Zobrazeno 1 - 10
of 183
pro vyhledávání: '"Manuel Anguita‐Sánchez"'
Autor:
Manuel Anguita‐Sánchez, José González‐Costello, Alejandro Recio‐Mayoral, José L. Rodríguez‐Lambert, Andrés Iñiguez‐Romo, Francisco Ruiz‐Mateas, Javier Elola‐Somoza, the Board of the Spanish Society of Cardiology
Publikováno v:
ESC Heart Failure, Vol 9, Iss 5, Pp 3649-3654 (2022)
Abstract Aims To describe logistics and outcomes of the accreditation program of centres of excellence in heart failure (HF) developed in Spain by the Spanish Society of Cardiology (SEC) between 2016 and 2021. Methods and results A scientific committ
Externí odkaz:
https://doaj.org/article/aa6c09f39df249bba443dda17bf8b0d4
Autor:
Jorge Perea-Armijo, José López-Aguilera, Rafael González-Manzanares, Cristina Pericet-Rodriguez, Juan Carlos Castillo-Domínguez, Gloria Heredia-Campos, Álvaro Roldán-Guerra, Cristina Urbano-Sánchez, Lucas Barreiro-Mesa, Nerea Aguayo-Caño, Mónica Delgado-Ortega, Manuel Crespín-Crespín, Martín Ruiz-Ortiz, Dolores Mesa-Rubio, Manuel Pan-Álvarez Osorio, Manuel Anguita-Sánchez
Publikováno v:
Journal of Clinical Medicine, Vol 12, Iss 18, p 6082 (2023)
Background: Worsening heart failure (WFH) includes heart failure (HF) hospitalisation, representing a strong predictor of mortality in patients with heart failure with reduced ejection fraction (HFrEF). However, there is little evidence analysing the
Externí odkaz:
https://doaj.org/article/b4c8c38febaf44d49a601c08c22dd86c
Autor:
Carlos González-Juanatey, Manuel Anguita-Sánchez, Vivencio Barrios, Iván Núñez-Gil, Juan José Gómez-Doblas, Xavier García-Moll, Carlos Lafuente-Gormaz, María Jesús Rollán-Gómez, Vicente Peral-Disdier, Luis Martínez-Dolz, Miguel Rodríguez-Santamarta, Xavier Viñolas-Prat, Toni Soriano-Colomé, Roberto Muñoz-Aguilera, Ignacio Plaza, Alejandro Curcio-Ruigómez, Ernesto Orts-Soler, Javier Segovia-Cubero, Víctor Fanjul, Judith Marín-Corral, Ángel Cequier, SAVANA Research Group
Publikováno v:
Journal of Clinical Medicine, Vol 12, Iss 16, p 5218 (2023)
Patients with type 2 diabetes mellitus (T2DM) and coronary artery disease (CAD) without myocardial infarction (MI) or stroke are at high risk for major cardiovascular events (MACEs). We aimed to provide real-world data on age-related clinical charact
Externí odkaz:
https://doaj.org/article/cba83f8acd5840bda48ab651b85bb9b7
Autor:
Carlos González-Juanatey, Manuel Anguita-Sánchez, Vivencio Barrios, Iván Núñez-Gil, Juan José Gómez-Doblas, Xavier García-Moll, Carlos Lafuente-Gormaz, María Jesús Rollán-Gómez, Vicente Peral-Disdier, Luis Martínez-Dolz, Miguel Rodríguez-Santamarta, Xavier Viñolas-Prat, Toni Soriano-Colomé, Roberto Muñoz-Aguilera, Ignacio Plaza, Alejandro Curcio-Ruigómez, Ernesto Orts-Soler, Javier Segovia, Víctor Fanjul, Ángel Cequier, SAVANA Research Group
Publikováno v:
Journal of Clinical Medicine, Vol 11, Iss 20, p 6004 (2022)
Patients with Type 2 diabetes mellitus (T2DM) and coronary artery disease (CAD) are at high risk of developing major adverse cardiovascular events (MACE). This is a multicenter, retrospective, and observational study performed in Spain aimed to chara
Externí odkaz:
https://doaj.org/article/a970ab137b8f44e592c73bdea02b9927
Autor:
Juan F. Delgado-Jiménez, Javier Segovia-Cubero, Luis Almenar-Bonet, Javier de Juan-Bagudá, Antonio Lara-Padrón, José Manuel García-Pinilla, Juan Luis Bonilla-Palomas, Silvia López-Fernández, Sonia Mirabet-Pérez, Inés Gómez-Otero, Antonio Castro-Fernández, Beatriz Díaz-Molina, Josebe Goirigolzarri-Artaza, Luis Miguel Rincón-Díaz, Domingo Andrés Pascual-Figal, Manuel Anguita-Sánchez, Javier Muñiz, María G. Crespo-Leiro
Publikováno v:
Journal of Clinical Medicine, Vol 11, Iss 5, p 1170 (2022)
Hyperkalaemia is a growing concern in the treatment of patients with heart failure and reduced ejection fraction (HFrEF) as it limits the use of some prognostic-modifying drugs and has a negative impact on prognosis. The objective of the present stud
Externí odkaz:
https://doaj.org/article/300905a990c54a0a9d15e4db238be82d
Autor:
José Antonio Gimeno-Orna, Luis Rodríguez-Padial, Manuel Anguita-Sánchez, Vivencio Barrios, Javier Muñiz, Antonio Pérez
Publikováno v:
Journal of Clinical Medicine, Vol 10, Iss 20, p 4634 (2021)
The objectives of this study were to determine the main characteristics associated with the presence of heart failure (HF) in patients with type 2 diabetes (T2DM), and specifically to assess the association of the risk classification proposed by the
Externí odkaz:
https://doaj.org/article/b5aaeb91b70947d09b82ee610cbab1b6
Autor:
Manuel Anguita-Sánchez, Pascual Marco-Vera, Francisco J. Alonso-Moreno, Fernando Arribas-Ynsaurriaga, Jaime Gállego-Culleré, Jesús Honorato-Pérez, Carmen Suárez-Fernández
Publikováno v:
Atención Primaria, Vol 48, Iss 8, Pp 527-534 (2016)
Objetivo: Estudios recientes han demostrado la eficacia y la seguridad de los nuevos anticoagulantes orales (NACO) en la prevención de tromboembolias en pacientes con fibrilación auricular no valvular (FANV). Nuestro objetivo es evaluar qué factor
Externí odkaz:
https://doaj.org/article/fd2aea9f56db4a07ad5887eb3993b48c
Autor:
Gloria Heredia Campos, Adriana Resúa Collazo, Consuelo Fernández-Avilés Irache, Paula Anguita Gámez, Juan C. Castillo Domínguez, Manuel Anguita Sánchez
Publikováno v:
Revista Española de Cardiología. 75:963-966
Autor:
Francisco Marin, Marcelo Sanmartín Fernández, Iñaki Lekuona, Fernando Arribas, Gonzalo Barón-Esquivias, Vivencio Barrios, Juan Cosin-Sales, Román Freixa-Pamias, Jaime Masjuan, Alejandro I Pérez-Cabeza, Vanessa Roldán Schilling, José Manuel Vázquez Rodríguez, Carles Rafols Priu, Manuel Anguita Sánchez
Publikováno v:
Journal of Comparative Effectiveness Research. 11:1173-1184
Objective: To analyze the effectiveness and safety of rivaroxaban in patients with atrial fibrillation (AF). Methods: The clinical profile and outcomes of the EMIR study were indirectly compared with those of ROCKET-AF, eight other Spanish observatio
Autor:
María A Esteve-Pastor, José M Rivera-Caravaca, Vanessa Roldán, Marcelo Sanmartin Fernández, Fernando Arribas, Jaime Masjuan, Vivencio Barrios, Juan Cosin-Sales, Román Freixa-Pamias, Esther Recalde, Alejandro I Pérez-Cabeza, José Manuel Vázquez Rodríguez, Carles Ràfols Priu, Manuel Anguita Sánchez, Gregory Y H Lip, Francisco Marin
Publikováno v:
Esteve-Pastor, M A, Rivera-Caravaca, J M, Roldán, V, Fernández, M S, Arribas, F, Masjuan, J, Barrios, V, Cosin-Sales, J, Freixa-Pamias, R, Recalde, E, Pérez-Cabeza, A I, Rodríguez, J M V, Priu, C R, Sánchez, M A, Lip, G Y H & Marin, F 2023, ' Predicting performance of the HAS-BLED and ORBIT bleeding risk scores in patients with atrial fibrillation treated with Rivaroxaban : Observations from the prospective EMIR Registry ', European heart journal. Cardiovascular pharmacotherapy, vol. 9, no. 1, pp. 38-46 . https://doi.org/10.1093/ehjcvp/pvac060
Background Assessing bleeding risk during the decision-making process of starting oral anticoagulation (OAC) therapy in atrial fibrillation (AF) patients is essential. Several bleeding risk scores have been proposed for vitamin K antagonist users but